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Abstract   
 Human proteins are vulnerable towards disease-associated single amino acid 
replacements affecting protein stability and function. Interestingly, a few studies have 
shown that consensus amino acids from mammals or vertebrates can enhance protein 
stability when incorporated into human proteins. Here, we investigate yet unexplored 
relationships between the high vulnerability of human proteins towards disease-
associated inactivation and recent evolutionary site-specific divergence of stabilizing 
amino acids. Using phylogenetic, structural and experimental analyses, we show that 
divergence from the consensus amino acids at several sites during mammalian evolution 
has caused local protein destabilization in two human proteins linked to disease: cancer-
associated NQO1 and alanine:glyoxylate aminotransferase, mutated in primary 
hyperoxaluria type I. We demonstrate that a single consensus mutation (H80R) acts as a 
disease suppressor on the most common cancer-associated polymorphism in NQO1 
(P187S). The H80R mutation reactivates P187S by enhancing FAD binding affinity 
through local and dynamic stabilization of its binding site. Furthermore, we show how a 
second suppressor mutation (E247Q) cooperates with H80R in protecting the P187S 
polymorphism towards inactivation through long-range allosteric communication within 
the structural ensemble of the protein. Our results support that recent divergence of 
consensus amino acids may have occurred with neutral effects on many functional and 
regulatory traits of wild-type human proteins. However, divergence at certain sites may 
have increased the propensity of some human proteins towards inactivation due to 
disease-associated mutations and polymorphisms. Consensus mutations also emerge as 
a potential strategy to identify structural hot-spots in proteins as targets for 
pharmacological rescue in loss-of-function genetic diseases.   
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Introduction 
 Through evolution, mutations causing single amino acid replacements may 
occur and fixate causing beneficial functional and stability changes (adaptive 
mutations), while others may not show any apparent change on protein functionality 
(neutral mutations) or affect secondary (promiscuous) functions, while largely 
deleterious mutations are more rarely fixed (1, 2). Random mutations are often 
destabilizing, particularly when they affect the protein core (3), and may reduce protein 
stability below a certain threshold impairing functionality and organism fitness, which 
in principle often prevents their fixation (2). Fixation of destabilizing mutations can be 
tolerated if other stabilizing mutations occur before or afterwards (2, 4). In this context, 
stability-activity trade-offs can be biologically buffered by different mechanisms, such 
as control of protein expression and modulation of protein misfolding by molecular 
chaperones (2, 5). Importantly, mutations often show pleiotropic effects, manifesting 
different effects on primary and secondary functions as well as on protein stability (2, 
4). Mutations can also contribute to the evolution of protein function and the acquisition 
of regulatory mechanisms involving protein allostery through modulation of the 
dynamics of protein conformational ensembles (1, 6-9). 
 The ability of proteins to fold into a native and stable structure intracellularly is 
often challenged by mutations, thus leading to disease (10, 11). During evolution, 
mammals have gathered a vast network of ∼1300 different proteins involved in protein 
biogenesis, folding, trafficking, degradation and maintenance of the proteome named 
the protein homeostasis network (10, 11). Mutations may critically affect the ability of 
proteins to fold and remain stable, causing loss of enzyme function and metabolic 
defects commonly due to accelerated proteasomal degradation (12). Global 
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destabilization of the protein structure due to single amino acid replacements may play 
an important role in this loss-of-function mechanism (13-15), although recent studies 
support the idea that local stability and dynamics of protein structures may drive their 
directional degradation via the proteasome (15-19). Accordingly, small molecules 
aimed at locally or globally stabilizing protein structure constitute a promising new 
battery of pharmacological tools to treat these diseases (12, 20-22). Mistargeting is 
another consequence of some mutations (23, 24), and the compartmentalization of 
metabolic pathways along evolution (25, 26) seems directly related to such mutations.  
 Proteins are often stabilized upon replacement of a rare amino acid at a given 
position by the most common one (i.e. the consensus amino acid) found in an alignment 
of homologous sequences (27-32). These back-to-consensus or consensus mutations 
increase protein stability primarily by local optimization of the interactions in the 
environment of the mutated site, and in some cases, by decreasing local flexibility (28, 
33, 34). It has been argued that consensus mutations are reversions to the ancestral 
amino acid, and thus, their stabilizing effect reflects to some extent the thermophilic 
nature of ancestral proteins (35-37), although the universality of this relationship is 
unclear (38). Consensus mutations can act as global intragenic suppressors by providing 
a stability boost towards destabilizing mutations (39). Since mammalian and vertebrate 
consensus amino acids can be strongly stabilizing when incorporated to human proteins 
(28, 32), it is intriguing that during the evolutionary history of mammals divergence 
from consensus amino acids may have yielded some human proteins more prone to 
loss-of-function and disease-causing mutations. 
 To investigate the evolutionary divergence of consensus amino acids as potential 
intragenic suppressors of human disease, we have chosen to study the most common 
cancer-associated polymorphism (rs1800566/c.C609T/p.P187S) in NAD(P)H:quinone 
Page 5 of 41 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
oxidoreductase 1 (NQO1) that causes a Pro187 to Ser187 amino acid replacement (40). 
This system is particularly suitable due to the multifunctional nature of this enzyme 
(allowing us to investigate specific effects on different individual functions) as well as 
the well-characterized mechanisms by which the polymorphism affects protein function 
and stability in vivo (18, 41-45). NQO1 is a homodimeric FAD-dependent enzyme 
involved in the activation of some anti-cancer pro-drugs (41, 46), which also interacts 
with and stabilizes transcription factors associated with cancer and cell-cycle regulation, 
such as p53, p73αLand HIF-1α (47, 48). While wild-type (WT) NQO1 is kinetically 
stable at physiological temperature in vitro (with a denaturation half-life of 9 h), the 
P187S polymorphism accelerates denaturation by a factor of 60 (43). More importantly, 
the P187S polymorphism largely abolishes NQO1 activity in vivo by affecting FAD 
binding and promotes its proteasomal degradation, through dynamic destabilization of 
two distant sites: the FAD binding site in the N-terminal domain (NTD, residues 1-224) 
and the small C-terminal domain (CTD, residues 225-274), respectively (18, 42, 44, 
49). As a consequence, binding of FAD to WT NQO1 protects it towards degradation in 
vivo while binding of the inhibitor dicoumarol is required to stabilize P187S, supporting 
a different directionality in their proteasomal degradation (i.e. initiated at the NTD vs. 
the CTD, respectively) and their specific blockage by ligands affecting protein local 
dynamics upon binding (18, 44, 45, 49).  
Results  
Stabilizing consensus amino acids have been replaced during recent divergent 
evolution of two disease-associated human proteins  
 To identify consensus mutations for NQO1, we have used an alignment of 
mammalian sequences, including those with high (over 80%) identity to that of human 
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NQO1 from eighteen different orders overall (SI text) and a large representation of 
those from primates (15.3%), rodents (19.2%), artiodactyla (15.3%), carnivora (11.5%) 
and chiroptera (9.6%). Among these consensus mutations, H80R causes the most 
remarkable stabilizing effect either in WT or P187S NQO1 (Figure 1A,B and Table S1), 
consequently increasing their kinetic stability (i.e. slowing down irreversible 
inactivation, Table S2). Importantly, H80R causes a local dynamic stabilization of the 
N-terminal domain (NTD) of WT NQO1, increasing by 2-fold its resistance towards 
partial proteolysis by thermolysin (Figure 1C and D), which occurs between Ser72 and 
Val73 (18). The H80R mutation has no effect on the sensitivity of P187S towards 
proteolysis (Figure 1C and D), showing that the local stabilization of H80R on the NTD 
does not propagate to the cleavage site of P187S found at its CTD (18). To provide 
structural insight for the stabilizing effect of H80R, we have solved the structure of 
H80R in the presence of FAD and dicoumarol (a competitive inhibitor of NADH; (41)) 
(Figure 1E, F and Table S3). The presence of the H80R mutation does not affect the 
overall fold of NQO1, with a RMSD of 0.42 Å (H80R, vs. WT, PDB ID: 2F1O, using 
PDBeFold (50)), showing two molecules of FAD and dicoumarol per dimer, and a third 
molecule of the inhibitor is found at the dimer interface (Figure 1E). Interestingly, 
Arg80 undergoes a transition to a less solvent exposed environment than that of His80 
(14 % vs. 30 %), and establishes a salt bridge with Glu78 (at 2.85 Å) and other 
electrostatic interactions mainly involving Lys59, and a water molecule (W88) 
hydrogen-bonded to Glu71 (not present in the WT enzyme; Figure 1F). Therefore, this 
cluster of electrostatic interactions mostly involving Glu71, Glu78 and Arg80 (hereafter 
named the “EER” cluster) appears to be critical for the local stabilization exerted by 
H80R. Importantly, the EER cluster seems to stabilize the adjacent loop 57-66, which is 
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highly dynamic in the P187S polymorphism and involved in its lower affinity for FAD 
(18).  
 Arg80 is found in most of the closely related mammalian sequences, suggesting 
that its stabilizing effect has disappeared recently in an evolutionary time scale. 
Specifically, this implies that the stabilizing effect of the consensus state at this position 
(i.e. Arg80) was present in mammalian ancestors of NQO1 and recently diverged to the 
non-consensus state found in the human enzyme (Figure 2). Consequently, Arg80 is 
present in rat NQO1, and its available X-ray crystal structure allows direct comparison 
of the structural consequences of the His-to-Arg transition in these orthologues with 
high (85%) sequence identity. Structural superposition of human WT and H80R 
enzymes with rat NQO1 show that the local structural switch triggered by Arg80 in the 
human enzyme is found in the murine enzyme (Figure 2A-B). In addition, the EER 
cluster is also structurally conserved in the murine protein, and Arg80 causes a similar 
local stabilization of the structure to that found in human H80R. The electrostatic local 
stabilization due to the EER cluster amounts to -1.8 and -2.3 kcal·mol-1 for human 
H80R and rat NQO1 compared to the human WT enzyme (Figure 2C). Overall, Arg80 
develops more stabilizing electrostatic interactions with its environment in rat than in 
human NQO1 (Figure 2C-D), mostly due to the presence of a non-conserved Glu59 in 
the rat enzyme which is a Lys in human NQO1 and most of the mammalian sequences. 
Nevertheless, a comparison of pairwise electrostatic interactions within the EER cluster 
(including Lys/Glu59), clearly shows that the local stabilizing role of the EER cluster 
found in human NQO1-H80R is present in the rat enzyme (Figure 2D). This EER 
cluster contains the largely stabilizing Arg80 in most of mammalian sequences of 
different orders, including different primate families, but sharply shifts to His80 in the 
hominidae family (Figure 2E-F), indicating that the Arg-to-His mutation has been 
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
recently fixed along primate evolution. Ancestral sequence reconstruction indicates that 
the Arg-to-His transition likely occurred after divergence of Cercopithecoidea and 
Hominoidea superfamilies from a common ancestor about 30 Myr ago (Figure 2G).  
 To test whether similar events to the recent Arg-to-His transition at position 80 
in mammalian NQO1 may have occurred in other consensus amino acids as well as for 
other proteins, we have performed consensus analyses using esentially the same set of 
mammalian species for NQO1 with human alanine:glyoxylate aminotransferase 1 
(hAGT). hAGT is associated, due to inherited mutations and the polymorphism P11L, 
with the life-threating disease primary hyperoxaluria type I (OMIM #259900), in which 
genetic variations cause loss-of-function of hAGT activity notably due to protein 
mitochondrial mistargeting and peroxisomal aggregation (23, 24). We have recently 
performed a detailed characterization of the effect of consensus mutations in hAGT, 
including quantitative stability and structural analyses for single- and multiple-
consensus mutants (28). As shown in Figure 3A, consensus analyses reveal a similar set 
of stabilizing mutations to that previously found using somewhat different groups of 
mammalian and eukaryotic sequences and experimentally validated for hAGT (28). 
Interestingly, murine orthologues of human NQO1 and hAGT (for which there are X-
ray structures) display a large fraction of these consensus amino acids (Figure 3B). 
 Detailed sequence, phylogenetic and structural analyses support the proposal 
that the fixation of a non-consensus (potentially disease-predisposing) amino acid in 
human NQO1 (i.e. His80) is not an unusual or isolated event (Figure 3, S1 and S2). 
Consensus amino acids are found in mammalian sequences with very high identity to 
the human orthologue, and divergence at these sites and consequent loss of stability 
seem to have occurred particularly along primate evolution (Figure 3B and C). Indeed, 
ancestral sequence reconstruction analyses support that about 70-80% of the 
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mammalian consensus amino acids analysed in NQO1 and AGT have been 
progressively replaced through the last 40 Myr (Figure 3D).   
 Our interpretation on the loss of stability due to divergence from consensus 
amino acids implies that their stabilizing effects on human NQO1 (this work) and 
hAGT (28) are conserved between highly similar orthologue proteins, a plausible 
assumption considering that site specific amino acid preferences are often highly 
conserved along evolution (39, 51). The available crystal structures for human and 
murine enzymes containing consensus amino acids at these sites provide further 
structural and energetic support for the interspecies conservation of the local 
stabilization exerted by consensus amino acids. Human and murine WT proteins, as 
well as human enzymes containing a single (NQO1-H80R) or multiple (hAGT-
RHEAM) consensus mutations share the overall fold (Figure S1A and S2A). In human 
NQO1, all six consensus mutations are individually stabilizing (Figure 1A), and only 
the adjacent A27V and A28E mutations are spatially close (Figure S1B), while the five 
consensus mutations on human AGT are individually stabilizing and their effects are 
additive (28), with four of them forming a intersubunit cluster of stabilizing interactions 
(Figure S2B). With a few exceptions, the consensus mutations do not cause large 
changes in the solvent accessibility (Figure S1C and S2C), and a significant fraction of 
them show an electrostatic origin for their stabilizing effects (Figure S1D and S2D). In 
rat NQO1, the consensus amino acids Arg80 and Glu28 combined cause a ≈3 kcal·mol-1 
stabilization compared to His80 and Ala28 in the human enzyme, due to local 
optimization of electrostatic interactions (Figure S1D,E and Figure 2). In mouse AGT, 
the consensus amino acids Arg23 and Glu52 create an electrostatic cluster of favourable 
interactions similar to that found in hAGT-RHEAM and including Arg175 and Arg333. 
This cluster amounts to 3-4 kcal·mol-1 of electrostatic stabilization, besides some small 
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differences with hAGT-RHEAM such as the absence of Glu344 in the mouse enzyme 
(Figure S2 D,E and (28)).  
 
The consensus mutation H80R rescues P187S NQO1 activity intracellularly 
through local stabilization of the FAD binding site without affecting the interaction 
with p73α.  
  To test whether mammalian consensus amino acids can act as suppressors of 
disease phenotype, we have further investigated the mutation H80R in the presence of 
the cancer-associated P187S NQO1 polymorphism. Notably, the local stabilization 
exerted by H80R at the NTD affects the environment of the FAD binding site (Figure 
4A), whose destabilization by P187S in the apo-state (particularly at the loop 57-66) 
causes enzyme inactivation by reducing the affinity for FAD (18). Accordingly, H80R 
increases the content in FAD of P187S as purified (Figure 4B), causing a concomitant 
large increase in specific activity (Figure 4C) without perturbing other kinetic properties 
(e.g. the apparent affinities for NADH and DCPIP as substrate; Table S4 and Figure 
S3). Results from thermal denaturation experiments with an excess of FAD ruled out 
that the stabilizing effect of H80R on P187S is due to the presence of higher FAD levels 
in the proteins as purified (Figure S4). Local stabilization of the FAD binding site of 
P187S by H80R also translates into a 10-fold higher binding affinity for FAD, with 
little consequence on the WT enzyme, as shown by fluorescence titrations (Figure 4D 
and S5). Molecular dynamics (MD) simulations recapitulate the structural switch caused 
by H80R (Figure S6) further showing that this switch dynamically stabilizes the loop 
57-66, particularly in the apo-state of P187S (Figure 4E,F).  
 The local stabilization exerted by H80R on the NTD should increase the FAD 
binding affinity of P187S, and consequently its activity inside cells, without affecting 
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degradation rates or protein levels (which are largely influenced by the dynamic CTD; 
(18)). We have thus investigated the effects of H80R on the intracellular activity, 
protein levels and degradation rates of WT and P187S by combining experiments in 
stably transfected Caco-2 cells (showing low endogenous levels of NQO1 protein due to 
being homozygous for P187S; (18)) with pulse-chase experiments in a rabbit 
reticulocyte cell-free system (Figure 4G-K). Western-blot analysis of transfected Caco-
2 cells reveal a 3-fold increase in protein levels of P187S in the presence of the 
suppressor H80R mutation, while this effect is weak in WT NQO1 (1.4-fold increase; 
Figure 4G and H). The levels of endogenous NQO1 P187S in Caco-2 cells (lower 
immunodetected bands in Figure 4G) are somewhat higher when cells are transfected 
with NQO1 variants containing the H80R mutation, suggesting that the presence of this 
mutation favors hetero-oligomerization between exogenous (i.e. transfected) and 
endogenous P187S NQO1. Since degradation of NQO1 proteins upon expression in 
rabbit reticulocyte extracts is mediated by the proteasome (52), we have used this 
system to determine whether H80R affects proteasomal degradation rates. The obtained 
results show that H80R has little effect on the degradation rates of WT and P187S 
(Figure 4I), suggesting that the effect of H80R on intracellular protein levels of P187S 
reflects an improved intracellular folding efficiency. Functional rescue of P187S by 
H80R is further supported by measurements of NQO1 activity in transfected cell 
extracts using DCPIP as substrate (Figure 4J) and corroborated by the increased 
capacity of intact transfected cells to activate the drug 17-AAG (17-N-allylamino-17-
demethoxygeldanamycin) into its cytotoxic form (53) (Figure 4K and S7). Importantly, 
NQO1 activity measurements (Figures 4J and K) correlate well with the levels of 
transfected NQO1 proteins (Figure 4G and I), supporting that hetero-oligomerization of 
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transfected proteins with endogenous P187S plays a minor role in the functional rescue 
exerted by H80R on P187S. 
 So far, we have shown that the consensus H80R mutation is capable of 
reactivating P187S NQO1 to a significant extent in vitro and in cells likely due to 
enhanced FAD binding affinity and folding efficiency. To determine whether this 
consensus mutation might affect further functions, such as their ability to interact with 
transcription factors (e.g. p73αLLLwe have usedLNMR spectroscopy to investigate 
binding of NQO1 variants with the C-terminal domain of p73αL(SAMp73αLL(49). 
Even though small quantitative differences are observed between NQO1 variants, these 
analyses support that the core of the residues involved in NQO1:SAMp73α interaction 
is not greatly affected by the H80R mutation (Figure S8 and Table S5).   
 
E247Q cooperates with H80R to rescue NQO1 P187S through long-range epistatic 
interactions 
 During the evolution of proteins, the effects of a single mutation often depend on 
the presence of additional mutations (a type of epistatic interactions; (2, 4)). In the 
context of this work, divergence from consensus amino acids at different sites in a short 
evolutionary time period (see Figure 3), may have cooperated to enhance the sensitivity 
of human NQO1 and AGT towards disease-associated inactivation through this type of 
interactions. This cooperation is further expected from the additive effects of consensus 
mutations on protein stability (28, 30, 54). To test this hypothesis, we have 
characterized the effects of the consensus NQO1 mutation E247Q, in the absence or 
presence of H80R (Figure 5). These two sites are not spatially close (at ∼40 Å) and the 
Glu247 is also far from the FAD binding site (at ~25 Å; Figure 5A). We found that 
E247Q locally stabilizes the CTD of P187S, decreasing by 2-fold the sensitivity to 
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partial proteolysis, and its effects propagate to the distal NTD enhancing the local 
stabilization exerted by H80R in the WT enzyme (Figure 5B). This long-range 
communication of the stabilizing effect of E247Q concomitantly increases the FAD 
content and specific activity of P187S, boosting the effects of H80R (Figure 5C-D). 
FAD titrations confirmed stronger binding of FAD to P187S in the presence of E247Q, 
particularly in combination with H80R (Figure 5E and S5), while very tight FAD 
binding was found for all variants of WT NQO1 (Figure 5F and S5). As described 
earlier in this work for H80R, the presence of E247Q did not largely affect the core of 
residues in SAMp73α involved in the formation of its complex with NQO1 (Figure S8 
and Table S5).  
 These results demonstrate that the additive stabilizing effects of consensus 
mutations can propagate to distal functional sites, in line with our recent findings on the 
long-range communication existing between the Pro187 site, the FAD binding site and 
the CTD, in particular when the CTD is withdrawn (49). Surprisingly, the epistastic 
effects described here for H80R and E247Q mutations support directionality in their 
propagation (in agreement with some ensemble descriptions of allosteric mutational 
effects; see (55)): the H80R mutation locally stabilizes the NTD, with no apparent 
effects on the stability or dynamics of the CTD (Figure 1C-D), while the E247Q 
mutation stabilizes the CTD and the distal NTD, and importantly, enhances the local 
stabilization exerted by H80R on the NTD (Figure 5B).  
 
Discussion 
 We have provided evidence supporting that consensus amino acids among 
mammalian sequences have diverged over the last 50 Myr, decreasing the local stability 
of some human proteins and potentially predisposing them towards disease-associated, 
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destabilizing and inactivating single amino acid changes. Due to the conservation of the 
stabilizing effect of consensus amino acids, at least in protein orthologues with highly 
similar sequences, their additive effects on stability, and the existence of long-range 
epistatic interactions between some consensus amino acids, it is intriguing to propose 
that some extant mammalian proteins (such as those from rodents) might be more 
robust towards disease-associated and destabilizing single amino acid replacements. 
Importantly, we demonstrate the potential of consensus amino acids to protect towards 
disease-associated single amino acid changes. This case also exemplifies well how 
deeply evolution can affect the protein conformational landscape through single 
mutations altering protein functionality in vivo, and particularly, the key role of long-
range propagation of structural and dynamic effects to different functional sites. An 
interesting application of consensus mutations as disease suppressors could be the 
identification of druggable spots in proteins, i.e. to mimic the suppressor effect of the 
mutation using small pharmacological ligands.  
 From the perspective of natural selection, it is difficult to conceive how 
destabilizing mutations diverging from consensus amino acids are fixed along 
evolution, unless the mutated sites are under low selective pressure. In this case, 
mutations diverging from the consensus amino acid would be eventually fixed if they 
have little or no effect on protein function in vivo (or ultimately, in the reproductive 
capacity of the species), therefore constituting networks of neutral mutations (or neutral 
networks; (2)). Indeed, this neutral network scenario explains well the experimentally 
observed effects on human NQO1 and AGT proteins (this work and (28)). In the case of 
NQO1, a paradigm of multi-functional stress protein, mutation of the consensus Arg80 
(to His) and Gln247 (to Glu) have little or no effect in many different molecular traits, 
such as its specific activity, FAD content, intracellular stability and folding efficiency, 
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or interaction with p73α. For human AGT, the simultaneous absence of up to five 
consensus amino acids only slightly affects its specific activity and has no impact on the 
intracellular folding, stability and peroxisomal import upon interaction with the 
peroxisomal receptor Pex5p (28). It can also be argued that the divergence of some 
consensus amino acids in these human proteins has been driven by natural selection, for 
instance by fine-tuning of some intracellular functions, unfortunately not yet identified 
by the functional analyses performed so far.   
 Our results with NQO1 have also important implications for understanding the 
stability and dynamics of the human flavo-proteome. A recent comprehensive 
proteomic analysis has shown that the stability of human flavo-proteins is strongly 
dependent on the bioavailability of the flavin cofactor, and NQO1 has emerged as a 
particularly sensitive case (45). Our results further highlight the importance of the apo-
state ensemble, in particular its structure, stability and dynamics (18, 42-45, 49, 56), in 
determining the cofactor binding affinity of human flavo-proteins, and consequently, 
their function and stability in vivo. This can be of particular relevance to understand the 
large number of metabolic diseases associated with flavo-proteins (linked to about 60% 
of all human flavo-proteins, based on a recent and exhaustive analysis (57)), and the 
significant fraction of them associated with riboflavin supplementation (57, 58).  
 
Materials and methods  
Consensus and phylogenetic analyses. The sequences of mammalian NQO1 and AGT 
enzymes were retrieved using BlastP and the human sequences as queries. This set of 
sequences (see SI) was used to identify consensus amino acids as those displaying the 
highest frequencies in the alignment. Therefore, the consensus ratio was defined as the 
number of sequences containing the most common amino acid in the alignment divided 
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by the number of sequences containing the amino acid found in the human protein at the 
same site. In NQO1, the six consensus mutations displaying consensus ratios higher or 
equal to 5 were selected for further characterization. 
 Phylogenetic trees based on the sequences of the NQO1 and AGT proteins were 
made according to the UPGMA method with the phangorn package (59) from the gnu-R 
statistical software. Analysis of time divergence was performed according to (60, 61). 
Materials. Antibiotics, HEPES, cacodylate, KOH, DCPIP, FAD, NADH and 
thermolysin from Bacillus thermoproteolyticus rokko were purchased from Sigma 
Aldrich (Madrid, Spain). Chromatographic columns for protein purification were from 
GE Healthcare (Barcelona, Spain). Concentration devices (cut offs of 3-30 kDa) were 
from Millipore (Madrid, Spain) or Sartorius (Madrid, Spain). Other chemicals were 
purchased from standard suppliers. 
Mutagenesis, expression and purification of NQO1 variants in E. coli. Site-directed 
mutagenesis was performed using the QuickChange lightening kit (Agilent 
Technologies, Madrid, Spain) by standard protocols and confirmed by sequencing. 
Expression in and purification from E. coli BL21 (DE3) was performed as described 
(43).  
In vitro characterization of NQO1 proteins. NQO1 activity was measured by 
following the reduction of DCPIP as described (49). FAD content in purified NQO1 
samples was estimated from UV-visible absorption spectra. Briefly, NQO1 proteins in 
K-HEPES 50 mM pH 7.4 were prepared ∼0.6 mg·mL-1 and the absorption spectra 
registered in a HP 8453 spectrophotomoter (Agilent) at 25oC. The corresponding 
spectra were converted into molar extinction units using a corrected extinction 
coefficient at 280 nm for each purified NQO1:   		 
    
 , that 
considers the contribution from apo-NQO1 (ε280= 47900 M
-1·cm-1, derived from the 
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primary sequence; (43)) and the FAD bound assuming that spectroscopic features of the 
cofactor do not largely depart from those in the free form (ε280= 22000 and ε450= 11300 
M-1·cm-1; (43)). This procedure yields estimates for the FAD content in purified 
samples by using a reference value of ε450= 11300 M
-1·cm-1 for 100% saturation. 
 Thermal denaturation of NQO1 proteins was determined in K-HEPES 50 mM 
pH 7.4 at a protein concentration of 2 µM in the presence of the fluorescent probe 
SYPRO Orange (Life Technologies, Madrid, Spain). Thermal scans were registered in a 
IQ5 Real-time PCR detection system (Biorad, Madrid, Spain) by monitoring 
fluorescence upon excitation at 460 nm and emission at 510 nm at a scan rate of 
0.5oC·min-1. The melting temperature was determined from the maximum of the first 
derivative (Tder) or as the half-denaturation temperature upon normalization of the 
unfolding curves (T0.5) as described (21). Additionally, thermal stability of NQO1 
proteins in the absence or presence of FAD (2 µM NQO1 monomer and 10 µM FAD) 
was determined by following intrinsic fluorescence (exc. 280 nm, em. 340 nm; slits 5 
nm) in K-HEPES 50 mM pH 7.4. Thermal scans were registered using 0.3 cm path-
length quartz cuvettes in a Cary-Eclipse spectrofluorimeter (Agilent Technologies), 
using 2oC·min-1 scan rate and Tm values determined as described above (T0.5 procedure). 
Data are reported as mean±s.d. from three independent scans. Inactivation kinetics was 
determined by incubation of protein samples (40 µM) for different times at 42oC, 
chilling on ice and measurement of residual activity as described (49). 
 Proteolysis kinetics by thermolysin were performed as recently described (18). 
Protease concentration was 100-200 nM (WT variants) or 0.5-1 nM (P187S variants). 
For each variant, two independent experiments were performed and data of intact 
NQO1 protein vs. time decays were used to determine first-order rate constants from 
exponential fits. These constants were divided by the thermolysin concentration used to 
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yield second-order proteolysis rate constants (kprot). For sake of comparison, ratios of 
kprot value for WT and the corresponding variant are provided, which indicate a 
stabilizing effect when these are larger than one and a destabilizing effect when lower 
than one. 
 Fluorescence titrations were performed at 25oC using 1 cm path-length cuvettes 
in a Cary Eclipse spectrofluorimeter (Agilent Technologies) and a final volume of 2 
mL. FAD was prepared in K-HEPES 50 mM pH 7.4 (at a final concentration 0-5  µM) 
in 1.9 mL and incubated for 5 min in the cuvette while the fluorescence of these blanks 
(exc. 295 nm; em.: 340 nm; slits 5 nm) was registered. Then, 100 µL of apo-NQO1 (4 
µM in monomer) was added, manually mixed, and fluorescence was measured for 10 
min to ensure proper equilibration. The fluorescence intensity of the last 60 s was 
averaged and the signal of the blank without protein was subtracted. Control 
experiments in the absence of FAD showed that apo-NQO1 did not significantly 
denature under these experimental conditions. For each protein variant, at least two 
different protein preparations and FAD stock solutions were used. Kd values were 
determined from fittings to 1:1 binding model using the following expression:  
       
  !"#$ !%&'( !"#$ !%&
)'
 
"#$ 

 *   
where F is the fluorescence intensity of the sample at a given total FAD concentration 
([FAD]), Fholo and Fapo are the intensities of the holo- and apo-proteins and [E] is the 
total concentration of NQO1 (0.2 µM in monomer). In all cases, fittings using this 
model provided a good description of the experimental data within the experimental 
uncertainty (Figure S5). 
 The interaction of NQO1 and SAMp73α was investigated by NMR 
spectroscopy. NMR data were acquired at 20 ºC on a Bruker Avance DRX-500 
spectrometer equipped with a triple-resonance probe and z-gradients. Samples 
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containing NQO1 proteins (at ~300 µM, in monomer units) and 15N-labelled SAMp73α 
(~120 µM) were prepared in 50 mM phosphate buffer pH 6.9. The 2D 1H-15N HSQC 
(heteronuclear single-quantum coherence) experiments (62) were acquired in the phase 
sensitive mode. Experiments were acquired and analyzed as described (49). 
Crystallography. Crystallization trials were carried out via the hanging-drop vapour 
diffusion method using previously reported conditions (63) at pH 7-9 and crystal 
improvement was achieved by the capillary counter diffusion technique (64) set-up 
using the Domino Granada Crystallization Boxes® (Triana Science & Technology, 
Granada, Spain). Good quality diffracting crystals were obtained using 30% of PEG 
3350, 200 mM sodium acetate, 100 mM sodium tricine pH 9.0, 1% DMSO and 10 mM 
dicoumarol, as precipitant agent. NQO1 H80R (70 mg·ml-1) mixed with agarose (0.05% 
w/v) was used to fill capillaries of 0.2 mm inner diameter. Crystals were equilibrated for 
24 hours with the mother liquid supplemented with 15% (v/v) glycerol before being 
extracted from the capillaries and flash-cooled in liquid nitrogen. Data were collected at 
ID-29 beam-line of the European Synchrotron Radiation Facility (ESRF, Grenoble, 
France) from flashed cooled crystals. Data were indexed and integrated using XDS (65) 
and scaled with SCALA from the CCP4 suite (66). The structure was determined by 
molecular replacement using the structure of WT NQO1 (PDB: 1D4A) without waters, 
as search model. The molecular replacement solution was found using Phaser (67) 
locating the two monomers in the asymmetric unit. Structure refinement was done with 
phenix.refine (68) with cycles of manual building steps and ligand identification 
performed with Coot (69). Titration-Libration-Screw (TLS) was included in the last 
steps of refinement. Model quality was checked using MolProbity (70) implemented 
within the Phenix suite (68). Coordinates and structure factors have been deposited at 
the PDB with accession code 5FUQ. Figures were prepared with PyMOL (71). Details 
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of data collection and processing, refinement statistics and quality indicators of the final 
model are summarized in Table S3.  
Electrostatic calculations. Calculation of the energy of charge–charge interactions (Eq-
q) was performed using the solvent-accessibility-corrected Tanford–Kirkwood model 
(72). The input for these calculations were the atomic coordinates of: human NQO1 WT 
(2F1O) and H80R (2FUQ), rat NQO1 (1QRD), human AGT WT (1H0C) and RHEAM 
(4CBS), and mouse AGT (3KGX). We used an in-house software (kindly provided by 
Prof. Jose Manuel Sanchez-Ruiz, Department of Physical Chemistry, University of 
Granada) at pH 7.4 and 0.025 M (for NQO1) or 0.2 M (for AGT) ionic strength. The 
output of these analyses provide the energy of charge–charge interactions of a given 
ionizable residue with all or individual ionizable residues in the protein dimer, and are 
expressed per ionizable residue. 
MD simulations. MD simulations were performed as recently described for WT and 
P187S NQO1 (18). The structures containing the mutation H80R were prepared using 
MOE (73) based on a crystal structure of the NQO1 complex with FAD (PDB: 1D4A) 
(63). The side-chain of Arg80 was modelled using two distinct conformations, solvent-
exposed and partially buried. Nevertheless, after an extensive equilibration protocol 
(74) and a 100 ns sampling simulation, we observed a consistent orientation for Arg80 
in the buried state after few ns. Analyses of MD trajectories were performed as recently 
described (18). 
NQO1 expression in Caco-2 cells. Caco-2 cells were grown and maintained in 
Dulbecco’s Modified Eagle Medium (Lonza, Barcelona, Spain) supplemented with 10% 
heat inactivated fetal bovine serum (HyClone, GE Healthcare, Barcelona, Spain), 100 
U·mL-1 penicillin and 100 µg·mL-1 Streptomycin (Sigma Aldrich, Madrid, Spain) and 
cultured at 37°C in a humidified incubator with 5% CO2. Cells were transfected using 
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Lipofectamine LTX with Plus Reagent (Thermo Fisher Scientific, Madrid, Spain) 
according to manufacturer’s protocol and pCINeo plasmids containing the cDNA of 
NQO1 enzymes and selected using 400 µg·mL-1 of G418 (Sigma Aldrich) for a month. 
 For immunoblotting, cells were scrapped and lysed in RIPA buffer (50 mM Tris-
HCl, 150 mM NaCl, 0.1% Triton X-100, 0.1% sodium dodecyl sulphate, 1 mM sodium 
orthovanadate, 1 mM NaF pH 8) with protease inhibitors (COMPLETE, from Roche, 
Spain). After centrifugation at 20000 g for 30 min, soluble extracts were collected and 
the amount of total protein determined by the BCA method (Pierce). Samples were 
denatured with Laemmli´s buffer under reducing conditions, resolved using 12% SDS-
PAGE and transferred to polyvinylidene difluoride membranes (GE Healthcare) using 
standard procedures. Immunoblotting was carried out using primary monoclonal 
antibodies anti-NQO1 and anti-β-actin (Santa Cruz Biotechnology) from mouse at 
1:500 and 1:10000 dilutions, respectively. As a secondary antibody, we used chicken 
anti-mouse IgG-HRP (Santa Cruz Biotechnology) at 1:2000 dilution. Protein bands 
were visualized using luminol-based enhanced chemiluminiscence and images were 
acquired with ChemiDoc MP imaging system and analyzed using Image Lab 5.0 
software (both from BioRad Laboratories). 
 For NQO1 activity measurements, cells were collected in 50 mM K-HEPES pH 
7.4 with protease inhibitors (COMPLETE, Roche) and lysed by freezing-thawing 
cycles. Soluble extracts were obtained upon centrifugation at 18000 g for 15 min at 4oC 
and total protein content was determined by the BCA method (Pierce) and immediately 
used for measurements. Activity measurements were carried out as described (18, 49) 
using DCPIP (75 µM) as electron acceptor and 0.5 mM NADH. Upon blank 
subtraction, the activity was normalized by the amount of total protein used in each 
measurement (50-130 µg).  
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 For 17-AAG activation assays, cells were dispensed in 96 well plates at a 
density of 2·104 cells/well. After 24 h, cells were treated with 0-30 µM 17-AAG (Santa 
Cruz Biotechnology). After two days of incubation, 20 µL of 0.125 mg·mL-1 of Alamar 
Blue solution (Sigma-Aldrich) was added to each well and incubated for 12 hours prior 
to absorbance measurement at 600 nm. Maximal inhibition of cell viability was 
determined from non-linear regression analysis of dose-response experiments. 
NQO1 expression in a cell-free system. Pulse-chase experiments were performed 
using a TnT rabbit reticulocyte cell-free system (Promega, Madrid, Spain) at 30 oC as 
described in (49). 
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Legends to Figures 
 
Figure 1. Structural basis of the global and local stabilization of human NQO1 by 
the consensus H80R mutation in vitro. A) Consensus mutations derived from 
mammalian NQO1 sequences stabilize NQO1; the consensus ratios and changes in 
denaturation temperature vs. WT (∆Tm; from T0.5 values in Table S1) are shown; B) 
Thermal stabilization of WT and P187S by the H80R mutation; data are means. from at 
least five experiments. Tm  from T0.5 values are shown (Table S1); C and D) Normalized 
proteolysis rates (C) and degradation patterns (D) for NQO1 enzymes showing local 
stabilization of the NTD by H80R. Normalized proteolysis rates are calculated from 
ratios of kprot (in M
-1·min-1) for WT/variants, and thus, values higher/lower than one 
reflect quantitatively the stabilizing/destabilizing effect, respectively; E and F) 
Structural comparison of H80R (PDB 5FUQ) and WT (PDB 2F1O) shows the 
preservation of the NQO1 overall fold (E) and the local stabilization exerted in the 
environment of the mutated site (F; WT in grey and H80R in pink). 
 
Figure 2. Overall conservation of the stabilizing effect of Arg80 across species and 
its divergence along primate evolution. A and B) Structural overlay of human NQO1 
WT (hWT, blue, PDB 2F1O) and H80R (hH80R, cyan, PDB 2FUQ) and rat NQO1 
(red, PDB 1QRD), showing the environment of the 80 residue and the loop 57-66 (A) 
and the EER cluster (B; values indicate solvent accesibilities); C) Total electrostatic 
interaction energies for individual residues of the EER cluster; D) Pairwise electrostatic 
interaction energies (in kcal·mol-1) between residue 59 and the EER cluster (residues in 
yellow are those diverging from human NQO1; the green and red color scale indicates 
the stabilizing/destabilizing nature of the interaction for visual aid); E and F) 
Page 33 of 41 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
Conservation of the EER cluster among representative individual mammalian sequences 
(panel E) and a set of fifty-three mammalian sequences (see SI text) grouped by 
order/family as sequences diverge in identity (F, circles indicate mean values and 
crosses their corresponding ranges); G) Ancestral sequence reconstruction for the Arg-
to-His transition at position 80.  
 
Figure 3. Recent evolutionary divergence of stabilizing consensus amino acids in 
NQO1 and AGT. A) Consensus analyses performed using a similar set of mammalian 
sequences for NQO1 and AGT; B and C) Divergence of the relevant set of consensus 
amino acids in highly similar mammalian sequences; in panel B, divergence is shown 
for individual sequences, in panel C as clustered in orders/families as the identity 
decreases (values are mean±s.d.; fifty-three sequences were used overall, see SI text); 
D) Phylogenetic trees based on sequences of NQO1 (left) and AGT (right). Numbers at 
some branches show the bootstrap values of 100 replicates. Only values above 50 are 
indicated. The lower panels show the aproximate times at which mutations have 
occurred according to ancestral sequence reconstruction. 
 
Figure 4. The H80R mutation protects cancer-associated P187S towards 
inactivation. A) Structural location of the loop 57-66 and His80 relative to the FAD 
binding site (PDB: 2F10); B) Absorption spectra of FAD bound to NQO1 enzymes as 
purified; data are the average from two independent purifications; the fractional degree 
of binding (in %) of FAD to NQO1 proteins is indicated; C) Activity of purified NQO1 
enzymes in the absence or presence of added FAD (mean±s.d. from 5-6 independent 
measurements); D) FAD titrations of apo-NQO1 proteins monitored by fluorescence; 
Data are from two independent experimental series. Best-fit Kd values are displayed; E 
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and F) Dynamic changes at residue level from MD simulations showing specific effects 
of H80R on the backbone dynamics of apo-P187S (highlighted by green circles).  G and 
H) representative western-blots of Caco-2 cells stably transfected with pCINEO (mock, 
no insert), pCINEO-NQO1 WT, H80R, P187S, H80R/P187S (panel G). The position of 
transfected (exogenous) NQO1 in the blots is indicated. In panel H, densitometric 
analyses of exogenous NQO1 protein normalized using  β-actin content (the signal of 
WT is set to 1 in each experimental series; n=3; mean±S.D.). Statistical differences are 
provided by an unpaired t-test; I) chase experiments after a pulse synthesis in rabbit 
reticulocyte extracts. Fits to a single exponential provide the half-lives for the 
corresponding NQO1 variants; mean±S.D. from three independent experiments; The 
inset displays a representative gel for a pulse of synthesis to show that proteins levels 
are comparable for all variants, although somewhat lower for P187S; J) NQO1 activity 
in Caco-2 cell extracts transfected with different NQO1 variants and using DCPIP as 
substrate; K) Capacity of different NQO1 variants to activate 17-AAG, determined as 
the maximal inhibition of cell viability and normalized using the value of Caco-2 cells 
transfected with pCINEO (mock)(see Figure S7). Data in J and K are best-fit 
values±standard errors and statistical significance is provided by a t-test. 
 
Figure 5. The consensus mutations E247Q and H80R cooperate to rescue P187S 
NQO1. A) Location of Glu247 far from His80 and the FAD cofactor (PDB 2F1O); B) 
Effect of the E247Q and H80R mutations on the normalized proteolysis rates by 
thermolysin; Normalized proteolysis rates were determined as described in Figure 1 and 
Materials and Methods; C) Absorption spectra of FAD bound to NQO1 enzymes as 
purified; data are the average from two independent purifications; the fractional degree 
of binding (in %) of FAD to NQO1 proteins is indicated; D) In vitro activity of purified 
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NQO1 proteins in the absence or presence of FAD 1 µM. E and F) Titrations of apo-
NQO1 variants (E, P187S variants; F, WT variants) with FAD followed by intrinsic 
fluorescence. Data are from two independent experimental series. Best-fit Kd values are 
displayed. 
 
Abbreviations 
AGT.- alanine:glyoxylate aminotransferase; CTD.- C-terminal domain; DCPIP.- 2,6-
Dichlorophenolindophenol; FAD.- flavin-adenin dinucleotide; HEPES.- 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid; MD.- molecular dynamics; NMR.- 
nuclear magnetic resonance; NQO1.- NAD(P)H:quinone oxidoreductase 1; NTD.- N-
terminal domain. 
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